News
12h
Zacks Investment Research on MSNBAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...
Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...
The FDA has updated the labeling for Kisunlaâ„¢ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results